You are here
Another Chinese pharma billionaire but where's the profit?
YOU don't need earnings to become a billionaire in China.
Ascletis Pharma Inc, a maker of HIV and liver-cancer drugs, has raised US$400 million after pricing its initial public offering at the middle of a marketed range at HK$14 a share. That would leave founder and majority owner Wu Jinzi with a fortune of about US$1.1 billion, according to the Bloomberg Billionaires Index. The company is expected to begin trading on Aug 1.
Started just five years ago, it's the first biotech company to take advantage of looser listing rules adopted in April by Hong Kong Exchanges & Clearing Ltd, paving the way for unprofitable firms in the industry to go public. Ascletis declined to comment on Mr Wu's net worth.
The drugmaker reported a net loss of 86.9 million yuan (S$17.3 million) last year, according to a prospectus, as the company has yet to generate sales.
Ascletis though does have deep-pocketed and savvy investors. It has raised US$155 million in two rounds of financing with backers including Goldman Sachs Group Inc and C-Bridge Capital.
"The healthcare sector is growing, while other sectors are slowing down," C-Bridge chief executive officer Fu Wei said. The Shanghai private equity firm, with US$1.4 billion under management, owns 12 per cent of Ascletis.
Mr Fu said the investment "lay the foundation for the company to grow" and accounted for more than half of Ascletis's pre-IPO funding. C-Bridge has no plans for similar investments beyond China, he said.
While China's pharmaceutical industry has produced at least 15 billionaires, as the country adopted rules for swift regulatory approvals, vaccine makers have become the target of a government crackdown after violations found at a manufacturer prompted a public outcry. Changsheng Bio-Technology Co was fined this month for selling low-quality vaccines for infants and fabricating production and inspection data for a rabies vaccine.
To tackle the scandal, China's securities regulator revised rules to suspend or delist companies involved in major illegal activities that include breaching production safety and public health.
Before founding Ascletis, Mr Wu worked for Novartis, Ambrilia Biopharma and GlaxoSmithKline. BLOOMBERG